BAY14-2222 Continuous Infusion in Surgeries

Inclusion Criteria: * Severe hemophilia A (FVIII:C \</=1%) * No history of FVIII inhibitor formation and no current evidence of inhibitor antibody (Bethesda Assay \< 0.6 BU) * Elective major surgery requiring at least 6 days of rFVIII-FS therapy * Subjects should have been previously treated with FVIII concentrates for at least 150 exposure days. Previous treatment could have been with any type of rFVIII or with plasma-derived FVIII concentrate or cryoprecipitate Exclusion Criteria: * Abnormal renal function (serum creatinine \>1.3 mg/dL) * Any treatments, which may change the clearance of FVIII (dialysis, plasma exchange) * Anemia (hemoglobin \<11 g/dL) * Known AIDS (HIV seropositive patients may be enrolled) * Active liver disease (transaminases \> 5 times the upper limit of normal) * History of severe reaction to FVIII concentrates * Interferon treatment within the last 3 months * Thrombocytopenia (\< 100,000 platelets/mm3) or other known hematological/bleeding problems other than hemophilia A * Intake of other investigational drugs within 1 month prior to study entry * Need for pre-medication for FVIII infusions (e.g. antihistamines) * Diastolic blood pressure \>100 mm/Hg, which could not be controlled with antihypertensive medications